Previous 10 | Next 10 |
SAN CARLOS, Calif., March 29, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will present at the follo...
SAN CARLOS, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will participate and present ...
Iovance Biotherapeutics, Inc. (IOVA) Q4 2018 Results Earnings Conference Call February 27, 2019, 04:30 PM ET Company Participants Timothy Morris - CFO Maria Fardis - President & CEO Debora Barton - SVP, Clinical Science Conference Call Participants Mark Breidenbach - Op...
- Patient Enrollment Commenced in the Registrational Cohort 4 in Study of Lifileucel in Advanced Melanoma - - FDA Granted Fast Track Designation for LN-145 for Treatment of Patients with Recurrent, Metastatic or Persistent Cervical Cancer - - Company to Host Conference Call at 4:30...
The FDA designates Iovance Biotherapeutics' (NASDAQ: IOVA ) cell therapy candidate LN-145 for Fast Track review for the treatment of recurrent/metastatic cervical cancer that has progressed on or after chemo. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Stocks on ...
SAN CARLOS, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the U.S. Food and Drug Administration (FDA) has g...
SAN CARLOS, Calif., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its fourth quarter and year-end 20...
In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more ...
by Jonathan Liss This week's Marketplace Roundtable podcast is with long-time Seeking Alpha contributor Bret Jensen . For the better part of a decade, Bret has been far and away one of SA's most prolific contributors. But don't confuse a steady output of single stock deep dive analys...
SAN CARLOS, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company will participate and present at the f...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-06-20 07:00:08 ET Reni Benjamin from JMP Securities issued a price target of $23.00 for IOVA on 2024-06-20 06:20:00. The adjusted price target was set to $23.00. At the time of the announcement, IOVA was trading at $8. The overall price target consensus is at $23.83...
2024-06-16 16:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-10 10:15:00 ET It's always a nice surprise to see that a company you're invested in is making good on its opportunities and planning to grow on your behalf. In that vein, at the 2024 meeting of the American Society of Clinical Oncology (ASCO) on May 31, Iovance Biotherapeutics ...